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ABSTRACT Experimental analysis of complex quantita-
tive genetic traits, such as essential hypertension, should be
greatly facilitated by being able to manipulate the expression of
a gene in living animals without altering the nudleotide se-
quence, chromosomal location, or regulatory elements of the
gene. To explore this possibility, we have used targeted gene
disruption and duplication to generate mice that are genetically
identical [(129 x C57BL6)Fl] except for having one, two, or
three functional copies of the gene coding for anglotensinen.
The two-copy animals have two normal copies of the angio-
tensinogen gene; the one-copy and three-copy animals have one
normal copy with the other either disrupted or duplicated by
gene targeting. The duplicated pair of genes was generated by
a special form of gap-repair gene targeting that tandemly
duplicates the whole of a gene together with 5' and 3' flanking
regions. We findprsely and signifcantly higher levels of
the gene product in the animals having increasing numbers of
gene copies: the one-copy animals have steady-state plasma
angiotensinogen levels -35% of normal (P < 0.0001), and the
three-copy animals have levels -124% of normal (P < 0.004).
Detailed information about regulatory sequences is not re-
quired for this.type of experiment; nor is it necessary to have
DNA clones or targeting constructs that cover the whole of the
target gene. Varying gene copy numbers by targeting conse-
quently offers a promising approach to quantitative genetics.
Essential hypertension is characterized by elevated blood
pressures without ascertained cause. Genetic and environ-
mental factors are significant in its etiology, with the former
being predominant (reviewed in ref. 1). Its mode of inheri-
tance is generally agreed to be polygenic, but specific genes
have not been definitively identified. Indeed, different com-
binations of genetic variations may be operating in different
individuals. One way of finding genes important in the
etiology of a disease is the "candidate gene" approach. A
candidate gene is chosen on the basis of nongenetic criteria,
such as physiologic relevance, and genetic linkage studies are
then carried out to look for cosegregation of polymorphic
forms of the candidate gene and the disease. Using this
approach, Jeunemaitre et al. (2) found evidence of genetic
linkage between certain variants of the human angiotensin-
ogen gene (AGI) and hypertension. [Angiotensinogen (AGT)
is an essential precursor of a potent vasopressive octapep-
tide, angiotensin II.] The specific variants proved to be
associated with an =20% higher level ofAGT in the plasma,
and the authors advanced the hypothesis that genetically
determined elevated AGT levels might be predisposing for
hypertension.
Our present experiments were initiated as the first step in
testing this hypothesis in mice. Specifically, we have gener-
ated mice having genetically determined gradations in their
steady-state plasma AGT levels, including levels close to
those seen by Jeunemaitre et al. (2) in their hypertensive
patients. The graded levels were achieved by using gene
targeting to derive mice that are genetically identical except
for having one, two, or three functional copies of the Agt
gene. Conventional gene targeting was used to produce the
one-copy mice. A special form of gap-repair gene targeting,
which we describe here, was used to produce the mice with
three gene copies.
MATERIALS AND METHODS
Cloning the Agt Gene. Genomic DNA was isolated from
E14TG2a (3) mouse embryonic stem (ES) cells and partially
digested with Mbo I. Approximately 15-kilobase (kb) frag-
ments prepared from this digest were used to make a library
in A phage Charon 35 (4). Clones containing portions of the
Agt gene were isolated by screening with a probe made by
PCR amplification of exon 2 of the mouse gene (5). An 8-kb
HindIII fragment of DNA (see Fig. 1A) extending 5' of the
transcriptional start of the gene was isolated from one of
these clones. A 1.8-kb fragment extending 3' ofthe transcrip-
tional stop was synthesized by PCR amplification using ES
cell genomic DNA as the template with primers designed
from the sequence of the mouse Agt gene (5). These two
fiagments were then used to make the gap-repair targeting
construct described below.
Cell Culture and Electroporation. Line E14TG2a ES cells
(3) were used for targeting and were cultured on feeder cells
as described (6). Electroporation (7) in the presence of the
linearized gap-repair targeting construct at a concentration of
2-5 nM used a 1-sec discharge from a 200-;F capacitor
charged to 300 V. Linearization of the plasmid construct was
achieved with the restriction enzyme Not I. Selection was
with G418 and ganciclovir (a gift from Syntex, Palo Alto, CA)
as described (6).
PCR Assay for Recombinants. Potential recombinants were
identified by a recombinant fragment assay for gene targeting
(8) that is based on PCR. PCR primer 1 is specific to the target
locus; it is from a part of intron 3 of the mouse Agt gene that
is within the 8-kb gap of the targeting construct; its sequence
is 5'-ACCACTCACGGAAGCTGCAT-3'. PCR primer 2 is
from the neomycin-resistance gene; its sequence is 5'-
ACGCGTCACCTTAATATGCG-3'. Cell lysates from indi-
vidual ES colonies surviving selection with G418 and ganci-
clovir were prepared (8) and amplified by PCR using primers
1 and 2. Amplification of a 2-kb fragment predicted from the
sequences of the Agt and neomycin-resistance genes was
taken as indicating a potential recombinant.
Southern Blot Analysis. Potentially recombinant colonies
were expanded to a level sufficient for Southern blot analysis,
which was carried out conventionally with probes specific for
exon 2 or 5 of the Agt gene.
Abbreviations: AGT, angiotensinogen; Agt, mouse angiotensinogen
gene; ES, embryonic stem.
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Plasma AGT Levels. Plasma AGT levels were determined
as angiotensin I equivalents by a radioimmunoassay for
angiotensin I scaled down from the manufacturer's protocol
(DuPont/NEN). Plasma samples (1 p1) had been incubated
for 1 hr at 37TC with 4 p1 of a renin-containing kidney extract,
prepared by homogenization of 14 adult mouse kidneys in 5
ml of 0.05 M sodium phosphate buffer (pH 7.4) followed by
centrifugation for 1 hr at 100,000 x g (9).
RESULTS AND DISCUSSION
Targeting Strategy for Gene Duplication. Fig. 1 illustrates
with the mouse Agt gene how gap-repair targeting with an
0-type (insertional) targeting construct can create a complete
tandem duplication of a gene. Targeting constructs to be used
in this way must include two regions of homology, one from
upstream (5') and a second from downstream (3') ofthe target
gene locus. To maximize the probability that both copies of
the tandemly duplicated gene will be fully functional, the 5'
and 3' flanking regions of homology should extend far enough
so that all known or suspected regulatory sequences can be
expected to lie between their respective 5' and 3' ends.
Spanning sufficient DNA to include all regulatory sequences
is facilitated by noting that (i) the flanking sequences do not
need to contain any coding sequences and (ii) they can be
separated by a large gap because of the gap repair described
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FIG. 1. Duplication of the Agt gene by gap-repair gene targeting.
(A) The structure of the target locus coding for AGT (adapted from
ref. 5). The line represents mouse genomic DNA sequences, with the
five exons ofthe gene shown as numbered black rectangles above the
line. HindIII and Sac I sites (H and S) used in Southern blot analyses
(see Fig. 2) are shown. (B) The linearized gap-repair targeting
construct used to create the tandem duplication. The two letters N
represent aNot I site that was used to linearize the construct. An 8-kb
gap that is in the targeting construct relative to the target Agt gene
is shown; it spans exons 2 and 3. Copies of the neomycin-resistance
(Neo) and herpes simplex thymidine kinase (TK) genes from
pMClNeo polA and pMC1TK polA (Stratagene) are indicated by
open and solid arrows. The interrupted line represents vector plas-
midDNA (not to scale in this part ofthe figure). (C) The chromosome
resulting from the homologous recombination that mediates the
gap-repair gene targeting. The 8-kb gap has been repaired by using
chromosomal information, and the Agt gene together with 5' and 3'
flanking regions has been tandemly duplicated. Two horizontal
square brackets indicate the duplicated region. Arrowheads 1 and 2
are primers for PCR (also indicated in A and B). Genomic DNA
fiagments that should hybridize to exon 2- or 5-specific probes after
successful gap-repair targeting are indicated by the double-headed
horizontal arrows; their predicted sizes are given in kilobases.
below. Duplication is therefore possible with genes that have
not been completely cloned or that are not available on a
single DNA fragment.
The extent of the duplication in this type of experiment is
determined by the distance in genomic DNA between the 5'
end of the upstream fragment of genomic DNA included in
the construct and the 3' end of the downstream region. There
is no obvious theoretical upper limit to the length of such
duplications, nor need the duplicated region include a gene.
In the present gap-repair construct (Fig. 1B) the 5' region
of homology (8 kb) extends about 3 kb 5' to the start of
transcription of the mouse Agt gene; the 3' region (1.8 kb)
extends about 200 bp 3' to the poly(A) addition site and
includes a 3' polypyrimidine tract. A gap of about 8 kb is
present in the targeting construct relative to the target Agt
gene; it spans exons 2 and 3. This gap is repaired (filled in)
during the homologous recombination that mediates gene
targeting. Such repairs, referred to as double-strand gap
repairs, use chromosomal information to supply the missing
sequences, as first described in yeast by Orr-Weaver et al.
(10) and in mammalian gene targeting systems by Valancius
and Smithies (11).
The gap in the construct serves three practical functions.
First, it allows the size of the construct to be less than the
gene that is to be duplicated; for example, in other experi-
ments we have duplicated 25 kb of DNA with a construct
having a total length of 15 kb and a gap ofover 16 kb. Second,
it allows a target-specific primer (primer 1 in Fig. 1) to be
chosen from genomic sequences that occur in the gap but not
in the incoming.DNA (11); this primer is needed for detecting
recombinants by PCR (8). Third, it provides a suitable
position within the construct for including a copy of the
herpes simplex thymidine kinase gene required for negative
selection with ganciclovir (12); this negatively selectable gene
is lost during the targeting. A positively selectable gene must
be included in the construct between the two regions of
homology. In the present construct we used the neomycin-
resistance gene, which allows positive selection with G418;
this positively selectable gene (shown by the open arrow in
Fig. 1C) is retained as a 1.1-kb insertion between the dupli-
cated genes after the targeting, as is the 3-kb vector plasmid
[pBluescript KS(+), Stratagene] shown by a broken line in
the figure.
Frequency of Gap-Repair Targeting. The targeting con-
struct, linearized with the restriction enzyme Not I, was
introduced into E14TG2a ES cells by electroporation. Col-
onies surviving positive/negative selection (12) with G418
and ganciclovir were assayed by PCR amplification with
primers 1 and 2 to identify potential recombinants (8). Pre-
vious studies by Valancius and Smithies (11) showed that
gaps of up to 2.5 kb in the targeting construct have essentially
no negative effects on targeting frequencies compared to
those seen with equivalent plasmids having a double-strand
break but no gap. Targeting with the construct illustrated in
Fig. 1B was also achieved at a frequency not significantly
different from that usually seen in gene targeting, despite the
presence of an 8-kb gap. Thus in two independent electro-
porations, gap-repair targeting was detected in 1 out of 72 and
in 10 out of 130 colonies surviving G418 and ganciclovir
selection, as judged by the PCR assay for recombinants.
Southern Blot Analysis. Southern blots were made with
DNA prepared from the 11 colonies judged recombinant by
the PCR assay. All gave the patterns expected from targeting
accompanied by repair of the 8-kb gap and tandem duplica-
tion of the Agt gene plus its 5' and 3' flanking regions.
Fig. 2 illustrates Southern blots of DNA from normal
untargeted ES cells (N) and from a gap-repair-targeted colony
(T). Digests were with Sac I or HindIII; hybridization was to
probes specific for exon 5 or 2, respectively, of the Agt gene.
Comparison of the sizes of the hybridizing bands with those
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FIG. 2. Southern blot analysis of digests of genomic DNA from
normal (lanes N) and gap-repair-targeted (lanes 1) ES cell colonies.
Digests with Sac I or HindIu were hybridized to probes specific for
exon 5 or exon 2, respectively. Fragment sizes in kilobases are given
for the bands that demonstrate successful targeting (see Fig. 1 for
their predicted sizes).
expected after successful gene duplication shows complete
agreement (see Fig. 1C for expected sizes). The targeted ES
cells have a normal Agt gene on one chromosome and a pair
of tandemly duplicated genes on its homologue; the relative
darknesses of the autoradiographic bands obtained with
DNA from the targeted cells can consequently be used to
check conclusions drawn from sizes. Thus the 3-kb Sac I
band and the 13.5-kb HindIII band, which come only from the
tandemly duplicated pair of Agt genes, should be-and
indeed are-approximately half as dark as the 5-kb Sac I and
14-kb HindIII bands, which come from both the singleton
Agt gene and the duplicated pair of genes. These data
therefore establish that gap-repair gene targeting was
achieved as illustrated in Fig. 1 and created a tandem gene
duplication at the target locus.
Generation of Mice. ES cells having the planned tandem
duplication of the Agt gene were injected into blastocysts in
a conventional manner to generate chimeras, and male chi-
meras were mated with inbred females of strain C57BL6.
Pups receiving the ES cell genome were identified by their
coat color (agouti). These agouti pups are all genetically
identical [(129 x C57BL6)F1] except for their sexes and their
genotypes at the Agt locus. As expected, about half (35/86)
of them inherited the duplicated Agt gene and consequently
have three copies of the Agt gene (we designate them 2/1,
since they have two Agt genes on one chromosome and one
on its homologue); the remainder are wild type (1/1) and have
two copies.
In a second set of experiments, to be described elsewhere,
we used conventional gene targeting to disrupt the Agt gene,
again in E14TG2a ES cells. From these modified cells we
generated chimeras, which were also mated with C57BL6
females. The agouti offspring from this second set of exper-
iments are identical [(129 X C57BL6)F1] to those from the
first set of experiments except for their Agt genotypes; about
half have only one functional copy of the Agt gene and are
accordingly designated 1/0. We therefore have available
males and females that are genetically identical except for
having one, two, or three copies of the Agt gene.
Plasma AGT Levels Versus Gene Copy Number. Plasma
samples were collected from three age-matched males and
three age-matched females of the three Agt genotypes (1/0,
1/1, and 2/1) and AGT levels were determined. Three to six
replicate measurements were made with every sample and
were averaged. The average values were then expressed as
percentages of the mean plasma AGT level for the six normal
(1/1) animals to facilitate pooling of data. Note that these
plasma AGT levels are steady-state levels, such as would
normally be measured in human subjects; no attempt has
been made to factor out the relative contributions to these
values of production, utilization, clearance, etc.
The means of the individual percent AGT levels were then
calculated for the six animals of each of the three genotypes.
Fig. 3 displays these means, together with their standard
deviations and the probabilities that the means forthe 1/0 and
2/1 animals differ significantly from that of the 1/1 animals.
The data show that the 1/0 animals have =%35% of the level
of normal 1/1 animals and that this difference is highly
significant (P < 0.0001 by the two-sample t test). The 2/1
animals have -124% ofthe level of 1/1 animals, and again the
difference is highly significant (P < 0.004). The conclusion is
therefore clear-an increasing number offunctional copies of
the Agt gene progressively and significantly increases the
level of its product. We stress that the increased AGT level
in the three-copy animals was achieved without altering the
nucleotide sequences of either of the duplicated gene copies
or their known regulatory elements and without changing
their chromosomal location. We therefore expect that the
duplicated Agt genes in these animals will have retained
their normal patterns of tissue expression and regulation.
This can be tested when 2/0 animals (see below) become
available.
The extent of the changes in the steady-state plasma AGT
level as the gene copy number varies requires comment. The
one-copy animals have considerably less (35%) than half the
plasmaAGT levels ofthe two-copy animals. The level (124%)
in the three-copy animals is also less than the value (150o%)
expected from strict proportionality to gene dosage. This
deviation from proportionality is not of great practical im-
portance at this stage ofour investigations, since determining
the effects on a downstream quantitative variable (in this case
blood pressure) of increasing or decreasing the level of a
specific gene product is not dependent on achieving some
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FIG. 3. Plasma AGT levels, presented as percentages ofthe mean
AGT values for normal (1/1) animals, versus the number of func-
tional copies ofthe Agt gene. The points on the graph show the mean
percentages, together with their standard deviations (also indicated
by error bars), for the six animals ofeach genotype that were tested.
(*, The mean of all the 1/1 animals is assumed to be 100%.) The Agt
genotypes of the animals, (1/0), (1/1), and (2/1), are shown. The
genetic background ofall the animals is identical: (129 x C57BL6)FI.
The probabilities, P. (calculated by the two-sample t test) that the
means for the 1/0 and the 2/1 animals differ significantly from that
of the 1/1 animals are displayed.
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plasma AGT levels in the three-copy animals is close to that
(20%) observed by Jeunemaitre et al. (2) in their hypertensive
patients. We thus anticipate being able to use our present
animals to test the hypothesis that genetically determined
elevations in plasma AGT levels in the range seen in humans
are predisposing to hypertension.
Nevertheless, the reasons for deviation from proportion-
ality are of interest. A likely explanation of the relatively
reduced plasma AGT levels in the one-copy animals is that
the amount ofAGT synthesized from one gene is insufficient
to maintain a half-normal steady-state plasma level in the face
of the prevailing level of utilization and clearance. At least
two factors could contribute to the nonlinear increase in AGT
in the three-copy animals: utilization may be increased when
AGT levels are above normal, and/or the pair of duplicated
genes may not function at the same level as two singleton
genes. The effectiveness of the duplicated Agt genes can be
rigorously tested, when the relevant animals become avail-
able, by comparing the AGT levels in normal two-copy
animals (1/1) with the levels in two-copy animals (designated
2/0) that are genetically identical except for having one
chromosome with the Agt gene duplicated and one chromo-
some with the Agt gene disrupted.
General Comments. In assessing the relative effects of
different genetic manipulations on a phenotype, particularly
if the effects are subtle and only quantitative, it is highly
advantageous to be able to keep all other genetic variables
constant. In our current breeding system, this was achieved
readily and rapidly by mating inbred strain 129-derived
chimeras with inbred strain C57BL6 animals to obtain ge-
netically uniform and vigorous (129 x C57BL6)F1 animals
that differed only in their Agt genotypes. Other breeding
schemes can achieve constant genetic backgrounds and an
even greater span of gene copy numbers, although at the
expense of hybrid vigor. For example, mating strain 129-
derived male chimeras to strain 129 females and using their
offspring for further breeding allows the production ofinbred
129 animals having 0, 1, 2, 3, or 4 copies ofthe Agt gene. The
2/0 animals required for the tests discussed above can be
produced by mating strain 129 three-copy (2/1) and one-copy
(1/0) animals.
An important consideration when exploring the effects of
gene dosage changes on a complex quantitative phenotype is
that the changes may have effects that are small or not
detectable. Past studies ofhumans and other animals hetero-
zygous (1/0) for a wide range of null mutations illustrate that
frequently the phenotypic effects of halving the number of
functional gene copies are subtle-possibly because the gene
product is normally in large excess, or because compensatory
changes occur in some related system. Indeed, much of the
difficulty of deciphering the intricacies of complex quantita-
tive genetic traits stems from such possibilities. Our scheme
does not remove these possibilities. Rather it provides ge-
netically uniform animals useful both for accurately assessing
their magnitude and for determining their relevance under a
variety ofconditions. For example, the achieved variations in
level ofexpression may prove to have inconsequential effects
under some environmental conditions but be important under
others. And study of the compensations induced by a single
genetic change is likely to indicate what other genetic sys-
tems merit study. The combined effects of changes in the
levels of expression of two independent genes can then be
studied.
Being able to genetically increase or decrease the expres-
sion of a gene, over ranges that are close to physiologic,
without deliberately changing the chromosomal location or
sequence of the gene and its regulatory elements appears
therefore to offer a promising approach to analyzing complex
quantitative genetic traits.
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